

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER

This announcement is made by Alphamab Oncology (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

### COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER

Reference is made to the announcement (the “**Announcement**”) of the Company dated June 2, 2025 in relation to, among other things, the Placing. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board has been informed by the Vendor that completion of the Placing took place on June 5, 2025. An aggregate of 14,600,000 Shares, representing approximately 1.51% of the issued share capital of the Company as at the date of this announcement (including treasury Shares), were successfully placed by the Sole Placing Agent at a price of HK\$8.05 per Share.

The respective shareholdings of the Vendor and other shareholders of the Company immediately upon completion of the Placing are set out below:

	<b>Shareholding immediately upon completion of the Placing</b>	
	<i>Number of Shares held</i>	<i>Approximate % of Shares in issue</i>
The Vendor	299,400,000 <sup>(1)</sup>	31.0%
Sky Diamond Co., Ltd.	85,750,000	8.9%
Pearlmed Ltd.	85,750,000	8.9%
Other shareholders of the Company	491,289,807	50.9%
Treasury Shares <sup>(2)</sup>	2,952,000	0.3%
<b>Total</b>	<b>965,141,807</b>	<b>100.0%</b>

*Notes:*

- (1) The entire share capital of the Vendor is wholly owned by New Xu's Family Trust, a discretionary trust established by Ms. Liu on April 10, 2023 with South Dakota Trust Company LLC acting as the trustee, of which Ms. Liu acts as the settlor and protector, and Dr. Xu acts as the investment advisor for the benefit of Ms. Liu's family members, including among others, Dr. Xu.
- (2) Representing the Shares repurchased by the Company and held as treasury Shares.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, June 6, 2025

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*